Progression of autosomal dominant kidney disease: measurement of the stage transitions of chronic kidney disease

Christopher M Blanchette, Caihua Liang, Deborah P Lubeck, Britt Newsome, Sandro Rossetti, Xiangmei Gu, Benjamin Gutierrez, Nancy D Lin

1University of North Carolina, Charlotte, NC, USA; 2Otsuka America Pharmaceutical, Inc., Princeton, NJ, USA; 3Optum Epidemiology, Waltham, MA, USA; 4Outcomes Insights Inc., Westlake Village, CA, USA; 5Denver Nephrologists, Thornton, CO, USA

Citation
Blanchette CM, Liang C, Lubeck DP, Newsome B, Rossetti S, Gu X, Gutierrez B, Lin ND. Progression of autosomal dominant kidney disease: measurement of the stage transitions of chronic kidney disease. Drugs in Context 2015; 4: 212275. doi: 10.7573/dic.212275

Copyright
Copyright © 2015 Blanchette CM, Liang C, Lubeck DP, Newsome B, Rossetti S, Gu X, Gutierrez B, Lin ND. Distributed under the terms of the Creative Commons Attributions License Deed CC BY NC ND 3.0 which allows anyone to copy, distribute, and transmit the article provided it is properly attributed in the manner specified below. No commercial use without permission.

Correct attribution
Copyright © 2015 Blanchette CM, Liang C, Lubeck DP, Newsome B, Rossetti S, Gu X, Gutierrez B, Lin ND. http://dx.doi.org/10.7573/dic.212275. Published by Drugs in Context under Creative Commons Attributions License Deed CC BY NC ND 3.0.

Article URL
http://www.drugsincontext.com/progression-of-autosomal-dominant-kidney-disease-measurement-of-the-stage-transitions-of-chronic-kidney-disease

Correspondence
Christopher M Blanchette, PhD, MBA, Associate Dean for Research & Public Engagement, Director of Data Sciences & Business Analytics, Associate Professor of Public Health Sciences, College of Health & Human Services, University of North Carolina at Charlotte, 9201 University City Boulevard, CHHS 476, Charlotte, NC 28223 USA. cblanche@uncc.edu

Provenance
Submitted, externally peer reviewed

Abbreviations
ADPKD, autosomal dominant polycystic kidney disease; ARPKD, autosomal recessive polycystic kidney disease; CKD, chronic kidney disease; eGFR, estimated glomerular filtration rate; ESRD, end-stage renal disease; ORD, Optum Research Database; RRT, renal replacement therapy; SCr, serum creatinine; UTIs, urinary-tract infections
Group Editor-in-Chief
Christopher Blanchette, PhD, MBA
Associate Dean for Research and Research Associate Professor in the Department of Public Health Sciences at the University of North Carolina and Director of Health Economics & Outcomes Research at Otsuka America Pharmaceutical Inc, USA

Expert Advisers – Epidemiology and biostatistics
Alex K Exuzides, PhD
Director, ICON Clinical Research Inc, California, USA
Professor Scott L Friedman, MD
Fishberg Professor of Medicine, Dean for Therapeutic Discovery Chief, Division of Liver Diseases, Mount Sinai School of Medicine, New York, USA
Carl De Moor, PhD
Senior Principal, Epidemiology and Leader Epidemiology, Safety and Risk Management Center of Excellence Americas, IMS Health Inc, USA
Dr John H Walker, OCT, MBA, PhD
Professor, Goodman School of Business, Brock University, St Catharines, Ontario, Canada

Specialist editorial board members
Deborah P Lubeck, PhD
Vice President, Outcomes Insights Inc, CA, USA

Specialist Advisor – Clinical Pharmacology
Dr Richard White, MA, PhD
Consulting Partner and Director, Oxford PharmaGenesis Ltd, UK

To see the full Drugs in Context Editorial Board, please visit www.drugsincontext.com/editorial-board

Expert Adviser – Publication Ethics
Dr Elizabeth (Liz) Wager
Publications Consultant, Princes Risborough, UK; Visiting Professor, University of Split School of Medicine, Croatia; Former Chair (2009-2012), Committee on Publication Ethics (COPE)

Editor-in-Chief Emeritus
Dr George Kassianos, FRCGP, FBHS, FESC, FBGTHA, FAcadMed, FFTM RCPSGlasg
General Practitioner, Bracknell, Berkshire, UK; President, British Global & Travel Health Association; Fellow of the European Society of Cardiology
Progression of autosomal dominant kidney disease: measurement of the stage transitions of chronic kidney disease

Christopher M Blanchette1,2, Caihua Liang3, Deborah P Lubeck4, Britt Newsome5, Sandro Rossetti2, Xiangmei Gu3, Benjamin Gutierrez2, Nancy D Lin3

1University of North Carolina, Charlotte, NC, USA; 2Otsuka America Pharmaceutical, Inc., Princeton, NJ, USA; 3Optum Epidemiology, Waltham, MA, USA; 4Outcomes Insights Inc., Westlake Village, CA, USA; 5Denver Nephrologists, Thornton, CO, USA

Introduction

Autosomal dominant polycystic kidney disease (ADPKD) is a progressive genetic disorder characterized by the development of numerous kidney cysts that result in kidney enlargement, which can lead to pain, hypertension, renal dysfunction and, ultimately, kidney failure [1,2]. ADPKD is the most common monogenic kidney disease in the USA and Europe [3,4]. Prevalence studies are outdated and have, in general, been conducted in small populations [5]. However, a recent landmark single-site study in the USA revealed the incidence of ADPKD to be ≈1:400 to 1:1000, depending on whether the estimation is based on symptomatic and family-screen cases or on autopsy data [6]. ADPKD is the leading inheritable cause of end-stage renal disease (ESRD) and one of the leading causes of ESRD overall [3,7]. ADPKD is also associated with a high financial burden. Total healthcare costs for ADPKD have been reported to be $51,048 per patient-year [8]. Also, predicted four-year healthcare costs by chronic kidney disease (CKD) stage have been estimated...
Hallmarks of ADPKD include development of numerous fluid-filled renal cysts that result in kidney enlargement, renal insufficiency, renal failure and, ultimately ESRD [10,11]. Progression of ADPKD is marked by declining kidney function along with increasing frequency and intensity of acute hospitalizations. Additional renal complications with ADPKD include urinary-tract infections (UTIs) and renal stones [1,2]. ADPKD is a systemic disease with complications arising from cysts developing in organs beyond the kidneys (most frequently in the liver and pancreas) as well as other extrarenal manifestations such as intracranial aneurysms, vascular events, cardiac events, and hematuria [1,2,12,13]. Hypertension in ADPKD patients is an early identifiable marker of renal disease and cardiovascular disease [1,12,14].

Little is known about the key characteristics and utilization of healthcare resources for patients with ADPKD along the continuum of disease progression. Increased understanding of the natural history of ADPKD may help identify patients at risk of rapid progression of, or the complications associated with, ADPKD, who could benefit from early treatment to potentially delay ESRD. The goal of ADPKD treatments for non-ESRD patients is control of blood pressure [15] and pain relief [16]. The goal of ADPKD treatments for ESRD patients is dialysis or transplantation. However, there remains an unmet need for treatments that slow or reverse ADPKD progression. Pharmacologic agents are being tested [17] and combination therapies have been suggested [18], but as yet there is no pharmacologic therapy indicated for ADPKD in the USA.

This observational study was designed to describe the characteristics of ADPKD patients and compare them with those of patients with other chronic kidney diseases. The primary objective was to describe the natural history of ADPKD in a real-world setting. The present study focused on: characterization of disease progression based on data from administrative claims; comparison of the characteristics among ADPKD patients vs. other CKD patients; characterization of a subset of ADPKD patients potentially at risk of rapid disease progression using validation of medical-chart reviews.

**Methods**

**Study design and data sources**

This was a retrospective observational cohort study using data on eligibility, pharmacy, medical claims, and electronic laboratory results from the Optum Research Database* (ORD). The ORD represents patients from a large health plan in the USA. The ORD is a proprietary research database containing medical and pharmacy claims with linked enrollment information from 1993 to the present. For 2012, data relating to ≈12.6 million individuals with medical and pharmacy benefit coverage were available. Laboratory data were available for a subpopulation of patients.

**Study population**

The study population comprised members of commercial health plans in the ORD who had a medical claim associated with a diagnosis of ADPKD or CKD between 1 January 2000 and 28 February 2013, the timeframe available for analysis. Overall requirements for inclusion were: continuous enrollment in the health plan with medical coverage and pharmacy benefits for ≥6 months before the earliest qualifying diagnosis of ADPKD or CKD (index date); continued complete medical coverage and pharmacy benefits throughout the period of observation within the study period.

For inclusion in the ADPKD cohort, patients had to have at least two claims for either of the following ICD-9 codes on separate dates: ICD-9-CM 753.12 (PKD, unspecified) or 753.13 (ADPKD), excluding claims for laboratories and diagnostic centers. Patients were excluded from the ADPKD cohort if they had a claim with a diagnosis code for autosomal recessive polycystic kidney disease (ARPKD, ICD-9-CM 753.14) at any time during the study baseline or follow-up period, or any evidence of kidney transplantation prior to the first diagnosis of ADPKD. A subset of ADPKD patients at potential risk of rapid progression during the study baseline or follow-up period was also identified based on one or more of the following: hypertension before the age of 35 years; hematuria before the age of 30 years; albuminuria at any time; advanced-stage kidney disease according to age (stage II by age 30 years, stage III by age 50 years, and stage IV/V, ESRD or transplantation by age 55 years). These criteria were identified based on a review of the literature on ADPKD [2,5,11–14,19,20].

Abstraction of medical records was undertaken for a subset of ADPKD patients who had only an ICD-9-CM diagnosis code of 753.12 (PKD, unspecified). Charts were used to validate the claims-based PKD diagnosis and to estimate the proportion of patients who had chart-confirmed ADPKD in the absence of a corresponding ICD-9-CM diagnosis.

For inclusion in the CKD cohort, patients had to have at least two claims for CKD (ICD-9-CM 585.1–585.9) on separate dates, excluding claims from laboratories or diagnostic centers. Patients with a claim for ADPKD (ICD-9-CM 753.13), PKD unspecified (753.12), or ARPKD (ICD-9-CM 753.14) at any time during the study period inclusive of the baseline period, as well as those with any evidence of kidney transplantation prior to the first diagnosis of CKD, were excluded. Patients meeting eligibility criteria for the CKD cohort were selected randomly so that the CKD cohort was threefold larger than the ADPKD cohort.

*Optum, Inc., USA
Measurement

Progression to a more severe stage of kidney disease, and the age at progression during the follow-up period, were the primary outcomes of the study. In a subgroup of patients with linked electronic data for laboratory results, identification of serum creatinine (SCr) results and calculation of estimated glomerular filtration rate (eGFR) was undertaken to determine the stage of kidney disease at baseline and during follow-up using the following quadratic equation with age, sex, and SCr [21]:

- \( \text{GFR} = \exp [1.911 + 5.249/\text{SCr} - 2.114/\text{SCr}^2 - 0.00686 \times \text{age} \times 0.205 \) (if female)]
- If SCr <0.8 mg/dL, SCr=0.8 was used (where SCr represents SCr in mg/dL)

Stage of kidney disease was defined based on the following classification of eGFR (in mL/min): stage I, ≥90; II, 60–89; III, 30–59; IV, 15–29; V, <15 (or on dialysis). Duration for stage transition was defined as the time interval between two consecutive stages, and was used to describe the time to the next stage at transition. Patients were assessed for forward transition(s); due to fluctuations in SCr, patients could appear to have a “backward” transition, but such transitions were not included in the assessment. Claims data were used to calculate time-to-ESRD overall and stratified by baseline stage of kidney disease starting from the day after index. Duration of follow-up for each cohort member extended from the day after cohort entry until either the first occurrence of a study event (e.g., ESRD), discontinuation from the health plan, or the end of the study period. However, a slightly higher percentage of CKD patients entered the cohort during the latter half of the study period (2006–2011). In addition, ADPKD patients were, in general, younger than CKD patients; 60.1% of patients in the ADPKD cohort were <50 years of age compared with 22.0% of patients in the CKD cohort. ADPKD patients also had a lower median number of visits to the physician compared with CKD patients.

Statistical analyses

Baseline descriptive characteristics were tabulated and stratified by cohort and stage. Number and percentage were calculated for categorical variables. Mean/standard deviation or median/interquartile range was calculated for continuous variables. The number of patients who transitioned to the next stage was tabulated to describe stage transition. Mean and standard deviation of age at each stage and the median and interquartile range of stage duration were described accordingly. Median survival times, incidence rates, and associated 95% confidence intervals for ESRD were estimated by study cohort and baseline stage. Kaplan–Meier plots were generated to depict the cumulative probability of event-free time among those with ADPKD, CKD, and those at risk of rapid progression.

Results

Characteristics of patients and the study

A total of 7,617 patients with ADPKD and 22,851 patients with CKD were identified, of which 4,101 ADPKD patients and 11,862 CKD patients had ≥1 SCr laboratory result during the baseline or follow-up periods (Figure 1). There were 3,415 patients with ADPKD who were identified as being at risk for rapid progression; 2,097 of these patients had ≥1 SCr laboratory result during baseline or follow-up. Charts for 146 patients with an unspecified diagnosis of PKD were procured, and 132 were determined by clinical reviewers to have sufficient information for ADPKD determination. Of these 132 patients, 125 were chart-confirmed to have ADPKD by a single clinical adjudicator, representing a positive predictive value of 94.7%. Demographic characteristics of ADPKD patients and CKD patients are described in Table 1.

Among patients with known stage at baseline, the highest proportion of patients with ADPKD were in stage I, and the highest proportion of patients with CKD were in stage V. Cohort entry of patients with ADPKD was, in general, distributed evenly across the study period. However, a slightly higher percentage of CKD patients entered the cohort during the latter half of the study period (2006–2011). In addition, ADPKD patients were, in general, younger than CKD patients; 60.1% of patients in the ADPKD cohort were <50 years of age compared with 22.0% of patients in the CKD cohort. ADPKD patients also had a lower median number of visits to the physician compared with CKD patients.

ADPKD patients tended to have a lower comorbidity score than CKD patients: 60.1% of ADPKD patients had a score of 0 compared with 34.9% of CKD patients (Table 2). ADPKD patients had a lower proportion of general comorbid conditions but were more likely to have UTIs, kidney stones, hepatic conditions, flank/abdominal pain, and kidney pain.

Distributions of demographic features and baseline clinical characteristics of ADPKD patients at risk of rapid progression (data not shown) were similar to those shown in Table 2 for the overall ADPKD group.

Stage transition

In both patients for whom the baseline stage was known (Table 3a) and those for whom initial stage was defined during follow-up (Table 3b), ADPKD patients were, in general, younger than CKD patients within the same stage and at transition to a more advanced stage based on recorded laboratory values. Among patients for whom the baseline stage was known and who started in stage I, median duration to stage II was 10.0 months for patients with ADPKD and 5.1 months for patients with CKD; median duration to stage III was 57.2 months and 7.3 months; to stage IV was 81.8 months and 15.0 months;
**Figure 1. Flow chart for the study.**

46,230,923 enrollees with complete medical coverage and pharmacy benefits between 1/1/2000 and 2/28/2013

- 15,627 patients with evidence of ADPKD
- 297,737 patients with evidence of CKD
- 8,018 patients meeting ADPKD inclusion criteria
- 181,872 patients meeting CKD inclusion criteria
- 401 excluded (ARPKD or baseline kidney transplant)
- 146 charts procured
- 125 confirmed ADPKD
- 7 confirmed not ADPKD
- 14 unknown
- 3,415 patients with potential for rapid progression (2,097 with ≥1 SCr result)
  - 999 baseline stage known
  - 1,098 stage identified in follow-up
- 4,101 patients with ≥1 SCr result
  - 1,962 baseline stage known
  - 2,139 stage identified in follow-up
- 11,862 patients with ≥1 SCr result
  - 7,305 baseline stage known
  - 4,557 stage identified in follow-up
- 22,851 patients in CKD cohort (a random sample of 3x number of ADPKD)
- 7,617 patients in ADPKD cohort (including PKD unspecified)

**ADPKD, autosomal dominant polycystic kidney disease; ARPKD, autosomal recessive polycystic kidney disease; CKD, chronic kidney disease.**

**Figure 2. Time-to-ESRD among ADPKD patients, CKD patients, and ADPKD patients at risk of rapid progression, overall.**

For the overall cohort, P<0.0001.
ADPKD, autosomal dominant polycystic kidney disease; CKD, chronic kidney disease; ESRD, end-stage renal disease.
Table 1. Demographic characteristics of ADPKD patients and CKD patients by disease stage at cohort entry: Optum Research Database, January 1, 2000–February 28, 2013.

| (n) | Overall (N=30,468) | Stage I (n=1,561) | Stage II (n=2,001) | Stage III (n=2,265) | Stage IV (n=743) | Stage V (n=2,697) | Unknown (n=22,201) |
|-----|--------------------|-------------------|--------------------|----------------------|-----------------|-----------------|------------------|
|     | ADPKD (7,617)      | ADPKD (627)       | ADPKD (934)        | ADPKD (343)          | ADPKD (1,658)   | ADPKD (1,937)   | ADPKD (2,199)    |
|     | (22,851)           | (22,851)          | (22,851)           | (22,851)             | (22,851)        | (22,851)        | (22,851)         |
| Age, n (%) |                     |                   |                    |                      |                 |                 |                  |
| <20 | 401 (1.3)          | 250 (1.7)         | 45 (2.6)           | 26 (2.8)             | 0 (0.0)         | 0 (0.0)         | 4 (0.0)          |
| 20–29 | 613 (2.0)          | 492 (3.2)         | 104 (5.5)          | 52 (5.6)             | 9 (1.0)         | 17 (2.0)        | 40 (1.5)         |
| 30–39 | 1,469 (4.8)        | 1,292 (8.1)       | 193 (10.1)         | 114 (12.2)           | 48 (4.6)        | 77 (9.0)        | 70 (2.9)         |
| 40–49 | 2,097 (7.0)        | 2,990 (18.4)      | 165 (8.7)          | 226 (12.0)           | 109 (12.6)      | 279 (33.2)      | 270 (10.0)       |
| 50–59 | 1,933 (6.3)        | 5,922 (37.9)      | 83 (4.3)           | 314 (16.8)           | 637 (35.4)      | 664 (33.3)      | 1,341 (50.0)     |
| 60–69 | 868 (2.9)          | 6,299 (39.7)      | 36 (1.9)           | 191 (10.2)           | 565 (34.1)      | 780 (40.3)      | 270 (12.6)       |
| ≥70  | 236 (0.8)          | 5,606 (35.3)      | 11 (0.6)           | 11 (0.6)             | 0 (0.0)         | 76 (4.6)        | 27 (1.2)         |
| Sex, n (%) |                     |                   |                    |                      |                 |                 |                  |
| Male | 3,622 (47.6)       | 13,614 (59.6)     | 230 (46.1)         | 461 (49.4)           | 144 (49.4)      | 510 (49.4)      | 1,251 (49.4)     |
| Female | 3,995 (52.4)       | 9,237 (40.4)      | 397 (47.3)         | 473 (50.6)           | 189 (45.1)      | 748 (40.6)      | 686 (50.6)       |
| Geographic area, n (%) |                     |                   |                    |                      |                 |                 |                  |
| Northeast | 771 (25.6)          | 1,888 (25.6)     | 71 (11.0)          | 67 (11.9)            | 22 (3.6)        | 100 (13.7)      | 197 (7.6)        |
| South  | 3,648 (47.9)       | 12,116 (25.9)     | 413 (65.9)         | 671 (71.8)           | 216 (36.0)      | 1,124 (19.5)    | 199 (60.7)       |
| Midwest | 1,921 (25.2)       | 5,298 (22.3)      | 67 (8.7)           | 81 (10.7)            | 47 (13.7)       | 167 (10.1)      | 47 (14.3)        |
| West   | 1,277 (16.8)       | 3,549 (22.7)      | 76 (11.5)          | 115 (12.3)           | 58 (16.9)       | 267 (16.1)      | 57 (11.9)        |
| Cohort entry, n (%) |                     |                   |                    |                      |                 |                 |                  |
| 2000–2001 | 839 (2.8)          | 1,031 (3.4)       | 27 (3.3)           | 3 (0.7)              | 19 (5.5)        | 11 (3.6)        | 15 (0.6)         |
| 2002–2003 | 1,115 (3.7)        | 1,550 (5.1)       | 84 (2.4)           | 41 (1.4)             | 52 (1.8)        | 37 (1.1)        | 42 (1.2)         |
| 2004–2005 | 1,237 (4.1)        | 2,233 (7.4)       | 104 (5.5)          | 55 (2.6)             | 47 (2.2)        | 76 (3.4)        | 58 (2.2)         |
| 2006–2007 | 1,367 (4.5)        | 5,177 (17.9)      | 98 (16.9)          | 169 (18.1)           | 61 (17.8)       | 247 (14.9)      | 62 (14.9)        |
| 2008–2009 | 1,393 (4.5)        | 5,363 (18.8)      | 149 (25.2)         | 252 (27.0)           | 69 (20.1)       | 476 (28.7)      | 60 (28.7)        |
| 2010–2011 | 1,176 (3.5)        | 5,420 (17.5)      | 115 (18.3)         | 288 (30.8)           | 69 (20.1)       | 637 (38.4)      | 67 (26.7)        |
| 2012–2013 | 490 (1.6)          | 2,077 (6.4)       | 50 (8.0)           | 126 (13.5)           | 26 (10.6)       | 175 (7.3)       | 24 (7.3)         |

Healthcare utilization during 6-month baseline period, median (IQR)

| Number of physician visits | Number of hospitalizations |
|---------------------------|---------------------------|
| 4 (2–6)                   | 0 (0–0)                   |
| 6 (3–9)                   | 0 (0–0)                   |
| 4 (3–7)                   | 0 (0–0)                   |
| 6 (3–9)                   | 0 (0–0)                   |
| 4 (3–7)                   | 0 (0–0)                   |
| 6 (4–10)                  | 0 (0–0)                   |
| 5 (3–8)                   | 0 (0–0)                   |
| 7 (4–11)                  | 0 (0–0)                   |
| 5 (2–8)                   | 1 (0–1)                   |
| 3 (2–6)                   | 1 (0–1)                   |
| 5 (3–9)                   | 0 (0–0)                   |

ADPKD, autosomal dominant polycystic kidney disease; CKD, chronic kidney disease; IQR, interquartile range.
## Table 2. Baseline clinical characteristics of ADPKD patients and CKD patients identified on the basis of healthcare claims, stratified by disease stage: Optum Research Database, January 1, 2000–February 28, 2013.

| (n)      | Overall (N=30,468) | Stage I (N=1,561) | Stage II (N=2,001) | Stage III (N=2,265) | Stage IV (N=743) | Stage V (N=2,697) | Unknown (N=22,201) |
|----------|---------------------|-------------------|--------------------|---------------------|------------------|-------------------|--------------------|
| ADPKD    | CKD                 | ADPKD             | CKD                | ADPKD              | CKD              | ADPKD            | CKD                |
| 0        | 4,580 (60.1)        | 7,967 (34.9)      | 436 (69.5)         | 363 (38.9)         | 196 (57.1)       | 744 (44.9)       | 36 (7.2)           | 22 (9.1)           | 3,746 (66.2)       | 5,921 (38.1)       |
| 1–2      | 2,461 (32.3)        | 9,338 (40.9)      | 162 (25.8)         | 392 (42.0)         | 125 (36.4)       | 641 (38.7)       | 113 (68.1)         | 303 (52.5)         | 299 (60.0)         | 1,605 (28.9)       |
| 3–4      | 464 (6.1)           | 3,806 (16.7)      | 22 (3.5)           | 102 (10.9)         | 15 (4.4)         | 179 (10.8)       | 15 (9.0)           | 94 (16.3)          | 123 (24.7)         | 639 (29.1)         |
| 5+       | 112 (1.5)           | 1,740 (7.6)       | 7 (1.1)            | 77 (8.2)           | 7 (2.0)          | 94 (5.7)         | 1 (0.6)            | 52 (9.0)           | 40 (8.0)           | 337 (15.3)         |

**Quan–Charlson Comorbidity Index score, n (%)**

| (n)      | Overall (N=2,601) | Stage I (N=124) | Stage II (N=932) | Stage III (N=1,032) | Stage IV (N=89) | Stage V (N=1,725) | Unknown (N=1,877) |
|----------|-------------------|-----------------|-----------------|---------------------|-----------------|-------------------|--------------------|
| ADPKD    | CKD               | ADPKD           | CKD             | ADPKD              | CKD             | ADPKD            | CKD               |
| 0        | 0.7±1.1 (1.6±1.9) | 0.6±1.1 (1.5±2) | 0.7±1.2 (1.3±1.7)| 1.2±1.2 (1.6±1.7) | 1.1±1 (1.9±2)  | 2.7±1 (2.6±2.1)  | 0.6±1 (1.5±1.8)   |

**General comorbid conditions, n (%)**

- **Genitourinary congenital anomalies:** 7,617 (100.0) / 551 (2.4)
- **Diseases of the urinary system:** 5,062 (66.5) / 22,851 (30.3)
- **Hypertension:** 5,021 (65.9) / 18,797 (23.6)
- **Disorders of lipid metabolism:** 2,211 (29.0) / 12,312 (15.9)
- **Heart diseases:** 1,731 (22.7) / 11,897 (52.1)
- **Respiratory infections:** 1,594 (20.9) / 5,397 (23.6)
- **Other diseases of the lower respiratory tract:** 1,123 (14.7) / 7,830 (34.3)
- **Diseases of arteries, arterioles, and capillaries:** 925 (12.1) / 6,645 (29.1)

**Specific comorbid conditions, n (%)**

- **Urinary-tract infection:** 1,208 (15.9) / 3,333 (41.4)
- **Kidney stone:** 639 (8.4) / 1,038 (4.5)
- **Pancreatic conditions:** 99 (1.3) / 521 (2.3)
- **Hepatic conditions:** 932 (12.2) / 2,184 (9.6)
- **Flank/abdominal pain:** 1,775 (23.3) / 4,024 (17.6)
- **Kidney pain:** 139 (1.8) / 143 (0.6)
- **Renal ultrasound:** 1,266 (16.6) / 4,257 (18.6)
- **Dialysis:** 376 (4.9) / 1,979 (8.7)

ADPKD, autosomal dominant polycystic kidney disease; CKD, chronic kidney disease; SD, standard deviation.
| Baseline stage | No transition/backward/missing | Transition to next stage during follow-up |
|----------------|--------------------------------|------------------------------------------|
|                | ADPKD | CKD | ADPKD | CKD | ADPKD | CKD | ADPKD | CKD | ADPKD | CKD | ADPKD | CKD |
| **Stage I, n** | 627   | 934 | 341/0/175 | 434/0/196 | 99    | 237 | 19    | 76  | 4     | 24  | 7     | 40  |
| Mean age, y±SD| 38.4±12.8 | 49.1±12.6 | 46.6±11.1 | 52.4±10.9 | 10.0  | 5.1 | 46.6±9.2 | 52.8±11.8 | 45.8±9.0 | 50.7±10.9 | 45.1±6.5 | 46.6±15.6 |
| Median stage duration, mo (IQR) | 10.0–23.7 | 1.4–10.8 | 7.2–12.8 | 1–18.4 | 81.8 | (51.9–90.1) | 15.0 | (9.1–27.7) | 55.6 | 2.4 | (36.0–58.1) | 0.2–171 |
| **Stage II, n** | 343   | 1,658 | 107/64/64 | 518/336/282 | 104   | 465 | 24    | 78  | 14    | 61  | 49.3±8.9 | 54.4±12.6 |
| Mean age, y±SD| 49.1±9.2 | 55.6±9.9 | 50.4±8.7 | 57.3±9.5 | 10.1  | 5.3 | 48.1±7.7 | 58.0±9.6 | 39.0 | 8.9 | 46.4 | (175–63.2) |
| Median stage duration, mo (IQR) | 4.7–23.9 | 1.5–13.0 | 17.9–61.0 | 2.5–26.2 | 17.5–63.2 | 1.2–22.9 |
| **Stage III, n** | 328   | 1,937 | 104/34/56 | 509/654/297 | 125   | 385 | 125   | 385 | 125   | 385 | 125   | 385 |
| Mean age, y±SD| 51.3±9.2 | 57.7±10.2 | 50.4±8.7 | 57.3±9.5 | 10.1  | 5.3 | 48.1±7.7 | 58.0±9.6 | 39.0 | 8.9 | 46.4 | (175–63.2) |
| Median stage duration, mo (IQR) | 4.7–23.9 | 1.5–13.0 | 17.9–61.0 | 2.5–26.2 | 17.5–63.2 | 1.2–22.9 |
| **Stage IV, n** | 166   | 577 | 38/21/18 | 98/175/82 | 16.2  | 6.2 | 41.8  | 13.8 | 41.8  | 13.8 | 41.8  | 13.8 |
| Mean age, y±SD| 51.4±8.6 | 55.0±12.4 | 6.8–31.4 | 2.4–16.6 | 29.1–58.6 | 4.3–28.5 |
| Median stage duration, mo (IQR) | 6.8–31.4 | 2.4–16.6 | 29.1–58.6 | 4.3–28.5 |
| **Stage V, n** | 498   | 2,199 | 451/23/24 | 1,815/230/154 | 89    | 222 | 89    | 222 | 89    | 222 | 89    | 222 |
| Mean age, y±SD| 52.9±10.7 | 53.2±14.2 | 50.9±8.5 | 54.0±12.7 | 9.0   | 7.8 | 50.9±8.5 | 54.0±12.7 | 3.9–18.5 | 2.4–17.8 |
Table 3b. Stage transition obtained from laboratory results among ADPKD patients and CKD patients: Optum Research Database, January 1, 2000–February 28, 2013; patients for whom the first stage was defined during follow-up.

| Stage, n | First stage during follow-up* | No transition/backward/missing | Transition to next stage during follow-upa |
|----------|-------------------------------|--------------------------------|------------------------------------------|
|          | ADPKD | CKD | ADPKD | CKD | ADPKD | CKD | ADPKD | CKD | ADPKD | CKD | ADPKD | CKD |
| Stage I |       |     |       |     |       |     |       |     |       |     |       |     |
|         | 816   | 616 | 411/0/302 | 283/0/213 | 94    | 103 | 13    | 24    | 3     | 6     | 6    | 8    |
| Mean age, y±SD | 37.4±12.8 | 47.2±14.0 | 48.1±9.9 | 53.4±11.4 | 44.8±6.0 | 53.1±13.8 | 52.0±8.0 | 54.2±11.4 | 38.3±15.8 | 46.5±19.3 |
| Median stage duration, mo (IQR) | 11.2 | 5.9 | (4.3–26.4) | (2.3–11.5) | 35.3 | 13.6 | 78.2 | 23.2 | 50.6 | 18.4 |
| Stage II |       |     |       |     |       |     |       |     |       |     |       |     |
|         | 378   | 957 | 133/56/85 | 372/120/211 | 101   | 235 | 18    | 24    | 5     | 12    |
| Mean age, y±SD | 47.5±10.2 | 57.8±10.7 | 51.4±9.2 | 60.8±9.9 | 50.0±10.8 | 57.7±13.3 | 50.0±7.4 | 57.0±10.9 |
| Median stage duration, mo (IQR) | 19.5 | (7.3–37.5) | 7.9 | (3.5–16.8) | 60.6 | 9.1 | 79.9 | (5.2–20.1) | 79.9 | (7.6–34.8) |
| Stage III |       |     |       |     |       |     |       |     |       |     |       |     |
|         | 321   | 1,069 | 130/38/52 | 423/226/216 | 89    | 175 | 45    | 58    |
| Mean age, y±SD | 49.8±11.1 | 59.3±12.1 | 50.7±10.8 | 59.1±12.8 | 52.7±8.7 | 56.4±12.2 |
| Median stage duration, mo (IQR) | 15.1 | (6.8–26.3) | 8.1 | (3.4–18.5) | 40.0 | 19.1 | (26.8–53.6) | 51.8±8.4 | 54.9±11.8 |
| Stage IV |       |     |       |     |       |     |       |     |       |     |       |     |
|         | 186   | 406 | 66/15/28 | 126/84/68 | 89    | 175 | 45    | 58    |
| Mean age, y±SD | 50.7±9.4 | 56.5±12.8 | 50.7±10.8 | 59.1±12.8 | 52.7±8.7 | 56.4±12.2 |
| Median stage duration, mo (IQR) | 15.1 | (6.8–26.3) | 8.1 | (3.4–18.5) | 40.0 | 19.1 | (26.8–53.6) | 51.8±8.4 | 54.9±11.8 |
| Stage V |       |     |       |     |       |     |       |     |       |     |       |     |
|         | 438   | 1,509 | 96/12/330 | 163/93/1,253 | 77    | 128 | 77    | 128 |
| Mean age, y±SD | 51.3±11.2 | 58.1±15.3 | 51.8±8.4 | 54.9±11.8 | 15.2 | 8.2 | (6.3–25.5) | (3.2–17.0) |

*Patients with more than one transition were counted more than once.

aMedian follow-up was 1.4–2.7 years for the ADPKD group and 1.0–2.1 years for the CKD group.

bMedian follow-up was 2.3–4.7 years for the ADPKD group and 1.8–2.7 years for the CKD group.

ADPKD, autosomal dominant polycystic kidney disease; CKD, chronic kidney disease; IQR, interquartile range; mo, months; SD, standard deviation; y, years.
Table 4. Stage transition obtained from laboratory results among patients at risk of rapid progression: Optum Research Database, January 1, 2000–February 28, 2013; (a) patients for whom the baseline stage was known, and (b) patients for whom the first stage was defined during follow-up.

(a) Transition to next stage during follow-up

| Baseline stage | No transition/backward/missing | Stage II | Stage III | Stage IV | Stage V |
|----------------|--------------------------------|----------|-----------|----------|---------|
| **Stage I, n** |                                |          |           |          |         |
| Mean age, y±SD | 33.3±11.0                      | 145/0/65 | 42        | 10       | 4       |
| Median stage duration, mo (IQR) | 40.2±9.5 | 43.7±9.0 | 45.8±9.0  | 43.3±4.8 |
| **Stage II, n** |                                |          |           |          |         |
| Mean age, y±SD | 44.6±9.3                       | 34/18/22 | 56        | 20       | 10      |
| Median stage duration, mo (IQR) | 46.9±8.5 | 39.0     | 47.6±7.5  | 47.6±8.3 |
| **Stage III, n** |                                |          |           |          |         |
| Mean age, y±SD | 47.5±9.1                       | 42/12/25 | 89        | 49.6±8.2 | 51.2±9.1|
| Median stage duration, mo (IQR) | 46.9±8.5 | 39.0     | 47.6±7.5  | 47.6±8.3 |
| **Stage IV, n** |                                |          |           |          |         |
| Mean age, y±SD | 48.1±7.6                       | 22/9/8   | 71        | 48.8±7.9 | 43.2    |
| Median stage duration, mo (IQR) | 46.9±8.5 | 39.0     | 47.6±7.5  | 47.6±8.3 |
| **Stage V, n** |                                |          |           |          |         |
| Mean age, y±SD | 47.8±8.4                       | 294/15/12| 8.9       | 8.9      | 8.9     |

(b) Transition to next stage during follow-up

| First stage during follow-up | No transition/backward/missing | Stage II | Stage III | Stage IV | Stage V |
|------------------------------|--------------------------------|----------|-----------|----------|---------|
| **Stage I, n**               |                                | 178/0/127| 43        | 11       | 2       |
| Mean age, y±SD               | 31.2±10.9                      | 43.2±10.1| 43.8±5.2  | 48.0±5.7 | 39.6±17.3|
| Median stage duration, mo (IQR) | 11.2 (3.6–26.4) | 35.3 (11.0–75.7) | 95.6 (78.2–113.0) | 82.8 (18.4–89.4) |
| **Stage II, n**              |                                | 53/28/19 | 47        | 14       | 4       |
| Mean age, y±SD               | 41.8±10.0                      | 46.7±8.7 | 47.2±10.4 | 48.5±7.7 |
| Median stage duration, mo (IQR) | 21.1 (9.0–39.2) | 65.2 (32.3–80.1) | 83.5 (57.0–103.3) | 8.9 (3.8–20.7) |
| **Stage III, n**             |                                | 52/18/23 | 68        | 46.7±11.2| 51.1±9.2|
| Mean age, y±SD               | 46.1±11.5                      | 15.4     | 45.8±11.2 | 45.8 (29.4–54.4) |
| Median stage duration, mo (IQR) | 15.4 (7.0–28.4) | 51.1±9.2 | 45.8±11.2 | 45.8 (29.4–54.4) |
| **Stage IV, n**              |                                | 33/8/11  | 57        | 48.8±7.1 | 13.3 |
| Mean age, y±SD               | 47.0±8.5                       | 15.4     | 48.8±7.1  | 13.3 |
| Median stage duration, mo (IQR) | 15.4 (7.0–28.4) | 51.1±9.2 | 45.8±11.2 | 45.8 (29.4–54.4) |
| **Stage V, n**               |                                | 67/8/239 | 57        | 48.8±7.1 | 13.3 |
| Mean age, y±SD               | 47.4±9.0                       | 15.4     | 48.8±7.1  | 13.3 |
| Median stage duration, mo (IQR) | 15.4 (7.0–28.4) | 51.1±9.2 | 45.8±11.2 | 45.8 (29.4–54.4) |

*Patients with more than one transition were counted more than once.

*Median follow-up was 1.3–2.7 years.

*Median follow-up was 2.3–4.7 years.

ADPKD, autosomal dominant polycystic kidney disease; CKD, chronic kidney disease; IQR, interquartile range; mo, months; SD, standard deviation; y, years.
and to stage V was 55.6 months and 2.4 months for patients with ADPKD and CKD, respectively. Among patients for whom the first stage was identified during follow-up and who started in stage I, median duration to stage II was 11.2 months for patients with ADPKD and 5.9 months for patients with CKD; to stage III was 35.3 months and 13.6 months; to stage IV was 78.2 months and 23.2 months, and to stage V was 50.6 months and 18.4 months for patients with ADPKD and CKD, respectively. Overall follow-up for these patients was 1.4–4.7 years for the ADPKD group and 1.0–2.7 years for the CKD group. Numbers of patients with no transition, missing a second SCr value, and those who had an apparent backward transition (potentially an artifact of recorded SCr levels) are also presented in Tables 3a and 3b, and the proportions were not substantially different between ADPKD and CKD groups.

Compared with overall ADPKD patients, similar median durations to transition to a more severe stage were observed among patients at risk of rapid progression in patients for whom the baseline stage was known (Table 4a) as well as those for whom stage was defined during follow-up (Table 4b). However, a younger age of stage transition was observed in all stages for patients at risk of rapid progression compared with overall ADPKD patients. Overall follow-up for these patients was 1.3–4.7 years. Time-to-ESRD was shortest among patients with ADPKD at risk of rapid progression, followed by CKD patients, and then ADPKD patients not at risk of rapid progression (Figure 2). In addition, progression to ESRD was most pronounced among those patients in advanced stages during the baseline period (Figure 3a–d).

**Discussion**

Understanding the natural history of ADPKD may help in the identification of patients who could benefit from early treatment and could potentially delay progression. We described the natural history of ADPKD in a large, geographically diverse commercially insured population in the USA over a long duration in a real-world setting.

---

**Figure 3.** Time-to-ESRD among ADPKD patients, CKD patients, and ADPKD patients at risk of rapid progression: baseline stage I (a), baseline stage II (b), baseline stage III (c), and baseline stage IV (d).  

| Stage | Survival Distribution Function |
|-------|--------------------------------|
| (a) Baseline stage I | CKD, Non-rapid progressors, Rapid progressors |
| (b) Baseline stage II | CKD, Non-rapid progressors, Rapid progressors |
| (c) Baseline stage III | CKD, Non-rapid progressors, Rapid progressors |
| (d) Baseline stage IV | CKD, Non-rapid progressors, Rapid progressors |

*Baseline stage I (a), P=0.0002; baseline stage II (b), P=0.7808; baseline stage III (c), P<0.0001; baseline stage IV (d), P<0.0001. ADPKD, autosomal dominant polycystic kidney disease; ESRD, end-stage renal disease; CKD, chronic kidney disease.*
In general, ADPKD patients were younger with a shorter median duration of health-plan membership and fewer physician visits, but had more specific comorbidities (e.g., UTIs, kidney stones, flank/abdominal pain, kidney pain) at the start of observation compared with CKD patients. Furthermore, in results unadjusted for differences between the two study populations, ADPKD patients had a longer time in the milder stages and longer duration before recorded transition to a more severe stage compared with CKD patients. Implications of these observations could be useful for determination of the transplantation eligibility of patients with ADPKD compared with the move to dialysis.

We also investigated a subgroup of patients considered to be at risk of rapid progression. These patients were younger at each stage, but had a similar recorded time to transition to a more severe stage compared with the overall ADPKD cohort, among patients with observed transitions to more severe stages. Criteria for entry into this cohort were based on reaching milestones at specific ages. Nevertheless, results suggested that age at transition to next stage may be useful for identification of ADPKD patients at risk of rapid progression, in combination with other measures (e.g., blood pressure, kidney stones, kidney size, number of kidney cysts). These results could be because the number of patients at risk of rapid progression transitioning to a more advanced stage was sparse, and because the ADPKD group included patients with ADPKD and PKD. However, the proportion of patients with PKD unspecified that had medical chart-specified ADPKD resulted in a positive predictive value of 94.7%.

Unadjusted time-to-event analyses suggested that ADPKD patients at risk of rapid progression (particularly those in stage III) had a shorter time-to-ESRD than patients with CKD and ADPKD patients not at risk. This phenomenon is most likely because cystogenesis is a constant event; therefore, if cysts are more plentiful and develop earlier, the disease progresses earlier, without increasing the time spent in each stage [22]. Time-to-event analyses also showed that progression to ESRD was most pronounced among patients in advanced stages during the baseline period.

Recent studies have begun to focus on the progression of ADPKD as well as the characteristics of ADPKD patients, highlighting the importance of studies that help to identify patients who may benefit from early treatment. Analyses of ADPKD progression between 1978 and 2012 in a natural-history setting found that a difference in eGFR decline can be predicted at least 10 years before the onset of ESRD [23]. In two recent studies by Higashihara et al., total kidney volume and eGFR were investigated for 39.7 months in 64 patients [24] and up to 13.9 years in 225 patients [25]. Results confirmed a declining rate of eGFR and increased total kidney volume as clinically meaningful markers in ADPKD.

Characteristics of ADPKD patients and treatment patterns over time were investigated in two recent studies. One study compared patients with ADPKD with non-ADPKD controls and investigated initiation of renal replacement therapy (RRT) [26]. The other study compared patients with ADPKD diagnosed between 1961 and 1990 with a cohort diagnosed between 1991 and 2011 [27]. The study investigating RRT found that neither change in age nor alteration in the male/female ratio among patients who started RRT changed over time [26]. It was speculated this observation was due to the disease impact of unmodifiable genetic factors in the absence of a specific treatment. The study comparing a diagnosis in an earlier timeframe versus in a later timeframe found an earlier age at the diagnosis, a lower mean blood pressure, better eGFR, and a longer timeframe from birth to ESRD and birth to death in the patients diagnosed in the later timeframe [27].

The studies described above underscore the importance of investigating progression of ADPKD as well as the characteristics of ADPKD patients. Unique characteristics of the present study are that disease progression and patient characteristics were described in a large retrospective cohort of ADPKD patients with a comparison cohort of CKD patients, both with a widespread geographic distribution. This comparison helps to place the data on ADPKD progression in context. In addition, the investigation of a cohort of patients at risk of rapid progression is helpful for obtaining more in-depth understanding of ADPKD patients.

A better overall knowledge of ADPKD that includes patient characteristics, disease progression, and utilization of healthcare resources is necessary to help identify treatments that may delay progression, increase the quality of life of patients, and reduce the utilization of healthcare resources associated with this disease.

Results of the present study increase our understanding of ADPKD, but study limitations should be noted. As mentioned above, the ADPKD cohort included PKD unspecified patients, which could have decreased the specificity of the ADPKD cohort. However, results from our sub-study on validation of PKD charts suggested a positive predictive value of 94.7% for classifying this group of patients as ADPKD patients. In addition, only results from laboratories reporting data to the ORD were available for stage analyses, so only ~25% of patients had SCr results available at baseline to determine disease stage. First stage was identified during follow-up in an additional 28% of patients. Moreover, for each of these groups, 25% of patients were in stage V or ESRD, and had already achieved maximum progression of disease. Finally, some misclassification of disease stage and timing of progression could occur due to (i) assignment of disease stage based on the earliest record of an eGFR (calculated based on SCr laboratory results) that met threshold criteria for a more advanced stage; (ii) variability in the timing or frequency of laboratory testing in clinical practice; and (iii) misclassification due to missing or inaccurate electronic laboratory results, serum inaccuracies, or lack of information on ethnicity which impacts calculation of eGFR from SCr.
The present study suggests that distribution of patients by age at transition to next stage may be useful for the identification of ADPKD patients at risk of rapid progression. It also suggests that medical claims with diagnosis codes for "unspecified PKD" can be used to describe disease progression. Future large, long-term cohort studies should continue to explore the genetic, clinical, and imaging characteristics of patients with ADPKD at risk of rapid progression who may demonstrate the greatest benefit from therapeutic interventions.

Contributions

Drs. Blanchette, Liang, Newsome, Rossetti, and Gutierrez contributed to the conception and design of this study. Supervisory contributions were made by Drs. Blanchette, Liang, Lubeck, Gutierrez, and Lin. Contributions to statistical analyses were made by Drs. Liang and Gu. All authors contributed to the writing, review, and revision of the manuscript. Drs Blanchette, Liang, Lubeck, Gu, Gutierrez, and Lin contributed to the analyses and interpretation of data.

Potential conflicts of interest

The International Committee of Medical Journal Editors’ (ICMJE) Potential Conflicts of Interests forms for the authors are available for download at: http://www.drugsincontext.com/wp-content/uploads/2015/04/dic.212275-COI.pdf

Sandro Rossetti is an employee of Otsuka America Pharmaceutical, Inc. Christopher M. Blanchette and Benjamin Gutierrez were employees of Otsuka Pharmaceutical Inc. during the study.

Caihua Liang, Nancy D. Lin, and Xiangmei Gu are employees of Optum Epidemiology and Deborah P. Lubeck is an employee of Outcomes Insights Inc.; both companies have received funds from Otsuka America Pharmaceutical, Inc., in connection with conduct of this study. Britt Newsome received funds from Otsuka America Pharmaceutical, Inc., in connection with conduct of this study.

Funding declaration

This study was sponsored by Otsuka America Pharmaceutical, Inc. (Princeton, NJ, USA). Medical writing and editorial support for preparation of this manuscript was provided by Scientific Connexions, Inc. (Lyndhurst, NJ, USA), an Ashfield Company, and funded by Otsuka America Pharmaceutical, Inc. None of the material in this manuscript has been presented previously.

References

1. Torres VE, Harris PC, Pirson Y. Autosomal dominant polycystic kidney disease. Lancet. 2007;369(9569):1287–1301. http://dx.doi.org/10.1016/S0140-6736(07)60601-1
2. Grantham JJ. Clinical practice. Autosomal dominant polycystic kidney disease. N Engl J Med. 2008;359(14):1477–85. http://dx.doi.org/10.1056/NEJMcp0804458
3. Chapman AB. Approaches to testing new treatments in autosomal dominant polycystic kidney disease: insights from the CRISP and HALT-PKD studies. Clin J Am Soc Nephrol. 2008;3(4):1197–1204. http://dx.doi.org/10.2215/CJN.00060108
4. Hildebrant F. Genetic kidney disease. Lancet. 2010;375(9722):1287–95. http://dx.doi.org/10.1016/S0140-6736(10)60236-X
5. Blanchette CM, Matter S, Chawla A et al. Burden of autosomal dominant polycystic kidney disease: systematic literature review. Am J Pharm Benefits. 2014 [Accepted for publication].
6. Iglesias CG, Torres VE, Offord KP, Holley KE, Beard CM, Kurland LT. Epidemiology of adult polycystic kidney disease, Olmsted County, Minnesota. Am J Kidney Dis. 1983;2(6):630–9.
7. National Institutes of Health. Fact Sheet – Autosomal Dominant Polycystic Kidney Disease. Available at: http://www2.niddk.nih.gov/ [Last accessed: July 10, 2014].
8. Brunelli SM, Blanchette CM, Claxton AJ, Roy D, Rossetti S, Gutierrez B. End-stage renal disease in autosomal dominant polycystic kidney disease: a comparison of dialysis-related utilization and costs with other chronic kidney diseases. Clinicoecon Outcomes Res. 2015;7:65–72. http://dx.doi.org/10.2147/CEOR.S76269
9. Blanchette CM, Lurga SR, Altan A et al. Healthcare resource utilization and costs associated with autosomal dominant polycystic kidney disease. JHEOR. 2014;2:63–74.
10. Grantham J, Cowley BJ, Torres VE. Progression of autosomal dominant polycystic kidney disease to renal failure. In: Seldin DW, Geibisch G, eds. The Kidney: Physiology and Pathophysiology. 3rd ed. Philadelphia: Lippincott Williams and Wilkins; 2000:2513–36.
11. Grantham JJ, Mulamalla S, Swenson-Fields KL. Why kidneys fail in autosomal dominant polycystic kidney disease. Nat Rev Nephrol. 2011;7(10):556–66. http://dx.doi.org/10.1038/nrneph.2011.109
12. Helal I, Reed B, Mettler P et al. Prevalence of cardiovascular events in patients with autosomal dominant polycystic kidney disease. Am J Nephrol. 2012;36(4):362–70. http://dx.doi.org/10.1159/000343281
13. Irazabal MV, Huston J 3rd, Kubly V et al. Extended follow-up of unruptured intracranial aneurysms detected by presymptomatic screening in patients with autosomal
dominant polycystic kidney disease. Clin J Am Soc Nephrol. 2011;6(6):1274–85.
http://dx.doi.org/10.2215/CJN.09731110

14. Ecder T. Cardiovascular complications in autosomal dominant polycystic kidney disease. Curr Hypertens Rev. 2013;9(1):2–11.
http://dx.doi.org/10.2174/1573402111309010002

15. Rahbari-Oskoui F, Williams O, Chapman A. Mechanisms and management of hypertension in autosomal dominant polycystic kidney disease. Nephrol Dial Transplant. 2014; 29(12):2194–201.

16. Davison SN, Koncicki H, Brennan F. Pain in chronic kidney disease: a scoping review. Semin Dial. 2014;27(2):188–20.
http://dx.doi.org/10.1111/sdi.12196

17. Wüthrich RP, Mei C. Pharmacological management of polycystic kidney disease. Expert Opin Pharmacother. 2014;15(8):1085–95.
http://dx.doi.org/10.1517/1465666.2014.903923

18. Aguiari G, Catizone L, Del Senno L. Multidrug therapy for polycystic kidney disease: A review and perspective. Am J Nephrol. 2013;37(2):175–182.
http://dx.doi.org/10.1159/000346812

19. Johnson AM, Gabow PA. Identification of patients with autosomal dominant polycystic kidney disease at highest risk for end-stage renal disease. J Am Soc Nephrol. 1997;8:1560–7.

20. Ecder T, Fick-Brosnahan G, Schrier RW. Polycystic Kidney Disease. In: Schrier RW, ed. Diseases of the Kidney and Urinary Tract, Vol. 2. 8th ed. Philadelphia: Lippincott, Williams & Wilkins, 2007.

21. Rule AD, Larson TS, Bergstralh EJ, Sleazak JM, Jacobsen SJ, Cosio FG. Using serum creatinine to estimate glomerular filtration rate: Accuracy in good health and in chronic kidney disease. Ann Intern Med. 2004;141(12):929–37.
http://dx.doi.org/10.7326/0003-4819-141-12-200412210-00009

22. Harris PC, Bae KT, Rossetti S et al. Cyst number but not the rate of cystic growth is associated with the mutated gene in autosomal dominant polycystic kidney disease. J Am Soc Nephrol. 2006;17(11):3013–9.
http://dx.doi.org/10.1681/ASN.2006080835

23. Thong KM, Ong AC. The natural history of autosomal dominant polycystic kidney disease: 30-year experience from a single centre. QJM. 2013;106(7):639–46.
http://dx.doi.org/10.1093/qjmed/hct082

24. Higashihara E, Nutahara K, Okegawa T et al. Kidney volume and function in autosomal dominant polycystic kidney disease. Clin Exp Nephrol. 2014;18(1):157–65.
http://dx.doi.org/10.1007/s10157-013-0834-4

25. Higashihara E, Horie S, Muto S, Mochizuki T, Nishio S, Nutahara K. Renal disease progression in autosomal dominant polycystic kidney disease. Clin Exp Nephrol. 2012;16(4):622–8.
http://dx.doi.org/10.1007/s10157-012-0611-9

26. Martinez V, Comas J, Arcos E et al. Renal replacement therapy in ADPKD patients: a 25-year survey based on the Catalan registry. BMC Nephrology. 2013;14:186.
http://dx.doi.org/10.1186/1471-2369-14-186

27. Helal I, McFann K, Reed B, Yan XD, Schrier RW. Changing referral characteristics of patients with autosomal dominant polycystic kidney disease. Am J Med. 2013;126:832e7-11.
http://dx.doi.org/10.1016/j.amjmed.2012.12.018